Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04781634 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

StatusRecruiting
PhasePhase 1/2
Started2021-03-07
View on ClinicalTrials.gov ↗

Amendment history

2025-02-23
Study Status, Oversight v3
Primary completion date2023-12-31→2026-12-31
Completion date2024-07-01→2027-07-01
2023-04-16
Study Status v2
Primary completion date2023-01-01→2023-12-31
Completion date2023-07-01→2024-07-01
2021-07-30
Active, Not Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusActive, Not Recruiting→Recruiting
Start date2021-01-01→2021-03-07
Study sitesdetails revised at 1 of 1 site
2021-03-02
Original filing
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL
Trial Details
NCT Number NCT04781634
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions B-ALL
Enrollment 40 participants
Start Date 2021-03-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-25